Cevira® is in development as a treatment for human papilloma virus (HPV) and precancerous cervical lesions (dysplasia). Selectively targeting the diseased area, Cevira is a treatment modality aiming to preserve the competence of the cervix.
The Cevira-device with an integrated light source.
Cevira may be a favourable alternative for treatment of hpv and cervical dysplasia
Photocure is developing breakthrough technology as a small, convenient, intravaginal, fully integrated drug delivery device for ease of use by the gynecologist. This treatment modality is based on our highly selective technology. Cevira is investigated as a treatment of HPV infections and a non-invasive treatment for patients with dysplasia.
Patients with HPV and cervical dysplasia experience distress due to frequent gynaecological examinations including Pap smears, HPV tests and biopsies with risk of progression due to poor sensitivity. In addition, surgical procedures including LEEP, LETZ, laser, cold knife and cryosurgery are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and pre-term labour in later pregnancies.
Cevira may be a favourable alternative for all these patients for several reasons:
- selective treatment of HPV infection and dysplasia
- aim to preserve normal cervical tissue
- preliminary data are indicative of few side effects
- easy procedure
Cevira combines drug and light in one easy device
Cevira treatment is administered locally to the cervix by the gynecologist, using the Cevira drug delivery device. After drug application the patient may return to normal daily activities. The device includes an integrated light source that automatically starts and stops for photoactivation of the drug. The device is removed by the patient when treatment is completed.
||The Cevira-device applied to the cervix
The product has completed phase IIb development and is expected to enter phase III in 2013.